Identification and in vivo efficacy of small-molecule antagonists of integrin αvβ3 (the vitronectin receptor)
- 1 September 2000
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 5 (9) , 397-408
- https://doi.org/10.1016/s1359-6446(00)01545-2
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Integrins as novel drug discovery targets: potential therapeutic and diagnostic implicationsEmerging Therapeutic Targets, 2000
- Inhibition of neointima formation by a nonpeptide ?v?3 integrin receptor antagonist in a rabbit cuff modelJournal of Cellular Biochemistry, 2000
- Synthesis and Biological Evaluation of Integrin Antagonists Containingtrans- andcis-2,5-Disubstituted THF RingsChemistry – A European Journal, 2000
- RGD Mimetics containing a central hydantoin scaffold: αVβ3 vs αIIbβ3 selectivity requirementsBioorganic & Medicinal Chemistry Letters, 2000
- ?v?3, ?v?5, and osteopontin are coordinately upregulated at early time points in a rabbit model of neointima formationJournal of Cellular Biochemistry, 1999
- Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (αvβ3) antagonistsBioorganic & Medicinal Chemistry Letters, 1998
- Integrins and anoikisCurrent Opinion in Cell Biology, 1997
- Solid-phase synthesis of a selective αvβ3 integrin antagonist libraryBioorganic & Medicinal Chemistry Letters, 1997
- Section Review: Cardiovascular & Renal: Glycoprotein IIb/IIIa antagonistsExpert Opinion on Therapeutic Patents, 1996
- Integrins: Versatility, modulation, and signaling in cell adhesionCell, 1992